Marilena Vrana Reflects on A Year of Growth, Gratitude, and Collective Strength
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”As the year draws to a close, it offers a natural moment to step back and acknowledge the growth, challenges, and progress that have shaped these past months.
Transitions in leadership are rarely seamless, and stepping into this new role mid-year came with a steep learning curve.
Yet through the transition came a clear lesson: leadership isn’t about having all the answers, but about creating the conditions where collaboration, curiosity, and courage can truly thrive.
This year showed again that resilience is built through collective effort.
The challenges we faced became catalysts for reimagining what’s possible, and our achievements became shared wins that strengthened the sense of purpose across the team, our membership, and the broader community of plasma and plasma-derived medicines.
What has truly fueled me throughout the year is the unwavering dedication of the PPTA Europe staff and members.
Your commitment to the mission, your integrity, and your persistence have shaped not only the milestones we reached, but also the “one-team” culture that continues to take root – grounded in trust, transparency, and shared responsibility.
As the year ends, I am deeply grateful for every colleague, partner, and supporter who contributed to this progress.
Thank you for your patience as I found my footing, for the feedback that sharpened our focus, and for the belief in what we’re building together.
In many ways, I’ve grown not just as a leader, but as a listener, a learner, and a teammate.
The year ahead holds promise with new opportunities, renewed momentum, and continued collaboration.
Here’s to building on this foundation together in the coming year, with purpose and optimism.”
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 16:53Flora Peyvandi: A New Approach to Coagulation with Bispecific Antibodies
-
Sep 10, 2026, 16:52Francisco Chacón-Lozsán: Perhaps We Are Treating ‘Sepsis’ When We Should Be Treating an Immune Phenotype
-
Sep 10, 2026, 16:46Aswin K Mohan: HLA Beyond Histocompatibility – Redefining Immune Recognition in Modern Medicine
-
Sep 10, 2026, 16:40Satyam Arora: Pediatric Apheresis – When Every Millilitre Matters
-
Sep 10, 2026, 16:39Marco Moscarelli: When CT Reveals Thrombosis After TAVI
-
Sep 10, 2026, 16:23Antonio Paul: When a Low Platelet Count Does Not Mean Weak Clotting
-
Sep 10, 2026, 16:12Balancing Thrombosis and Bleeding in Antiphospholipid Syndrome
-
Sep 10, 2026, 16:07Miguel Teran: Why ROTEM Will Redefine Major Bleeding Management
-
Sep 10, 2026, 16:04Isaac Okello: Where Skyline Meets Savannah – Quiet Moments at GASCDO in Nairobi